MX2017009643A - Composiciones y métodos de uso de inhibidores de tirosina quinasa. - Google Patents

Composiciones y métodos de uso de inhibidores de tirosina quinasa.

Info

Publication number
MX2017009643A
MX2017009643A MX2017009643A MX2017009643A MX2017009643A MX 2017009643 A MX2017009643 A MX 2017009643A MX 2017009643 A MX2017009643 A MX 2017009643A MX 2017009643 A MX2017009643 A MX 2017009643A MX 2017009643 A MX2017009643 A MX 2017009643A
Authority
MX
Mexico
Prior art keywords
methods
phosphorylation
tyrosine
compositions
kinase inhibitors
Prior art date
Application number
MX2017009643A
Other languages
English (en)
Spanish (es)
Inventor
Bennett Anton
Sung YI Jae-
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2017009643A publication Critical patent/MX2017009643A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2017009643A 2015-01-26 2016-01-26 Composiciones y métodos de uso de inhibidores de tirosina quinasa. MX2017009643A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107553P 2015-01-26 2015-01-26
US201562250052P 2015-11-03 2015-11-03
PCT/US2016/014882 WO2016123086A1 (en) 2015-01-26 2016-01-26 Compositions and methods of using tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2017009643A true MX2017009643A (es) 2018-05-04

Family

ID=56544226

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009643A MX2017009643A (es) 2015-01-26 2016-01-26 Composiciones y métodos de uso de inhibidores de tirosina quinasa.
MX2022012505A MX2022012505A (es) 2015-01-26 2017-07-25 Composiciones y metodos de uso de inhibidores de tirosina quinasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012505A MX2022012505A (es) 2015-01-26 2017-07-25 Composiciones y metodos de uso de inhibidores de tirosina quinasa.

Country Status (6)

Country Link
US (4) US10471059B2 (enExample)
EP (2) EP3250192B1 (enExample)
JP (4) JP6854766B2 (enExample)
CN (2) CN113244399A (enExample)
MX (2) MX2017009643A (enExample)
WO (1) WO2016123086A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN106943595A (zh) * 2017-03-30 2017-07-14 福州大学 Src/Abl抑制剂作为预防或治疗辐射损伤药物的应用
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US20210196714A1 (en) * 2018-06-18 2021-07-01 Duke University Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
EP4775207A2 (en) * 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
FI3930715T3 (fi) * 2019-02-27 2024-08-05 Astrazeneca Ab Sarakatinibi käytettäväksi idiopaattisen keuhkofibroosin hoidossa
WO2021119525A1 (en) * 2019-12-11 2021-06-17 Tiaki Therapeutics Inc. Shp1 and shp2 inhibitors and their methods of use
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
WO2022125551A1 (en) * 2020-12-07 2022-06-16 Hht Foundation International, Inc. Method of treating hereditary hemorrhagic telangiectasia using pazopanib
WO2023127012A1 (ja) * 2021-12-27 2023-07-06 国立研究開発法人理化学研究所 動脈瘤の治療及び／又は予防のための医薬組成物、動脈瘤の診断補助方法、並びに動脈瘤治療薬の評価方法
WO2023175136A1 (en) * 2022-03-18 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis
CN116832040B (zh) * 2023-06-12 2026-01-13 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
CN122349433A (zh) * 2023-08-10 2026-07-07 英矽智能科技知识产权有限公司 用于治疗子宫内膜异位症的方法和药物
WO2025111752A1 (zh) * 2023-11-27 2025-06-05 中山大学 以Lck/Fyn介导STAT3磷酸化为靶点的阻断剂和生物材料的用途
WO2025170008A1 (ja) * 2024-02-07 2025-08-14 国立大学法人京都大学 成熟心筋細胞の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355786B1 (en) 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
CA2388343A1 (en) 1999-11-12 2001-05-17 Mark Steven Marshall Methods for inhibiting neurofibromatosis type 1 (nf1)
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2579519A1 (en) 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
US20070015777A1 (en) 2005-07-14 2007-01-18 Myogen, Inc. Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
US20070123539A1 (en) * 2005-10-20 2007-05-31 University Of South Florida Treatment of Restenosis and Stenosis with Dasatinib
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
US8283441B2 (en) * 2006-10-31 2012-10-09 University Of Toledo Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP2359813A1 (en) 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
JP2016506417A (ja) * 2013-01-10 2016-03-03 プルモキネ、インコーポレイテッド キナーゼ阻害剤の治療指標
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Also Published As

Publication number Publication date
EP3250192A4 (en) 2018-09-26
EP4653015A3 (en) 2025-12-31
CN107530298A (zh) 2018-01-02
JP2025061369A (ja) 2025-04-10
EP3250192B1 (en) 2025-10-08
CN107530298B (zh) 2021-06-04
US20230036788A1 (en) 2023-02-02
CN113244399A (zh) 2021-08-13
MX2022012505A (es) 2022-11-07
JP2018504416A (ja) 2018-02-15
US20180271864A1 (en) 2018-09-27
HK1245678A1 (en) 2018-08-31
EP3250192A1 (en) 2017-12-06
EP4653015A2 (en) 2025-11-26
JP2021050218A (ja) 2021-04-01
JP6854766B2 (ja) 2021-04-07
JP7840031B2 (ja) 2026-04-03
US11458137B2 (en) 2022-10-04
WO2016123086A1 (en) 2016-08-04
JP2023052878A (ja) 2023-04-12
US10471059B2 (en) 2019-11-12
US20200009142A1 (en) 2020-01-09
US20250360129A1 (en) 2025-11-27
CA2974958A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
MX2022012505A (es) Composiciones y metodos de uso de inhibidores de tirosina quinasa.
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
MX2020001103A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
BR112022003543A2 (pt) Inibidores de kras g12
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
EA201791258A1 (ru) Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112017023225A2 (pt) inibidor de proteína cinase
BR112022021381A2 (pt) Compostos para o tratamento de sars
BR112018074238A2 (pt) combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
CL2020003010A1 (es) Moduladores de la expresión de apol1
MX2021012749A (es) Inhibidor selectivo de la jak1 cinasa.
CO2022000270A2 (es) Inhibidores de enzimas